All Stories

  1. Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
  2. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
  3. Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
  4. Effect of ambroxol on whole lung mucociliary clearance in sheep
  5. An assay for inhibitors of PDE12 (2´- Phosphodiesterase) to test many compounds very fast.
  6. Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats
  7. The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis
  8. Molecular cloning of a macrophage-derived, interferon-inducible secreted immunoglobulin-binding protein
  9. The role of peptide presentation in the physiological function of HLA-G
  10. Cell lines transfected with the TAP inhibitor ICP47 allow testing peptide binding to a variety of HLA class I molecules [In Process Citation]
  11. Interferon-Induced Expression ofIf-1handIf-llAlleles in Newcastle Disease Virus-Infected Mouse Macrophages Is Associated with Specific Differences in Viral Gene Transcription
  12. Inhibition by interleukin-4 of constitutive beta interferon synthesis in mouse macrophages